IVERIC bio (NASDAQ:ISEE) Stock Price Down 9.8% After Insider Selling

IVERIC bio Inc (NASDAQ:ISEE)’s stock price was down 9.8% during mid-day trading on Wednesday following insider selling activity. The company traded as low as $7.57 and last traded at $7.61, approximately 853,513 shares changed hands during mid-day trading. A decline of 7% from the average daily volume of 922,183 shares. The stock had previously closed at $8.44.

Specifically, CEO Glenn Sblendorio purchased 15,000 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were purchased at an average cost of $3.12 per share, for a total transaction of $46,800.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Keith Westby sold 4,530 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.60, for a total value of $29,898.00. Following the sale, the chief operating officer now owns 45,106 shares in the company, valued at $297,699.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,465 shares of company stock valued at $120,649. 4.30% of the stock is owned by corporate insiders.

Several equities analysts recently commented on the stock. ValuEngine raised shares of IVERIC bio from a “strong sell” rating to a “sell” rating in a research note on Friday, January 3rd. Wedbush assumed coverage on shares of IVERIC bio in a research note on Monday. They issued an “outperform” rating on the stock. Finally, Chardan Capital reissued a “hold” rating and issued a $1.25 price target on shares of IVERIC bio in a report on Wednesday, September 18th.

The company has a market cap of $338.06 million, a PE ratio of -4.55 and a beta of 1.97. The stock has a 50-day moving average of $5.81 and a 200-day moving average of $2.54.

IVERIC bio (NASDAQ:ISEE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter.

Several large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new stake in shares of IVERIC bio during the 2nd quarter valued at about $29,000. A.R.T. Advisors LLC purchased a new stake in IVERIC bio in the second quarter valued at approximately $31,000. Wells Fargo & Company MN purchased a new stake in IVERIC bio in the second quarter valued at approximately $36,000. Charles Schwab Investment Management Inc. purchased a new stake in IVERIC bio in the second quarter valued at approximately $39,000. Finally, Northern Trust Corp bought a new stake in IVERIC bio during the second quarter valued at approximately $114,000. 37.17% of the stock is currently owned by hedge funds and other institutional investors.


IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).

See Also: How Does the Quiet Period Work?

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit